Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE) [Thoracic Oncology]

Conclusion
The 5-year OS and PFS rates in randomly assigned patients with resectable stage III non–small-cell lung cancer were excellent with both treatments. Both are acceptable strategies for this good-prognosis group.

Source: Journal of Clinical Oncology - December 8, 2015 Category: Cancer & Oncology Authors: Eberhardt, Pottgen, Gauler, Friedel, Veit, Heinrich, Welter, Budach, Spengler, Kimmich, Fischer, Schmidberger, De Ruysscher, Belka, Cordes, Hepp, Lutke-Brintrup, Lehmann, Schuler, Jockel, Stamatis, Stuschke Tags: Combined Modality Thoracic Oncology Source Type: research